Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers

References

• NIMH: Schizophrenia. Bethesda, MD; 2018. Available at: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml [Accessed January 28, 2018]
   Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 2016;77:764-71
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014;29:63-76
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67(3):453–60
   Web of Science ®Google Scholar
• Lindenmayer J-P, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009;70:990-6
   PubMed Web of Science ®Google Scholar
• Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. Pharm Ther 2014;39:638
   Google Scholar
• Bellack AS, Bowden CL, Bowie CR, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1-48
   PubMedGoogle Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32
   PubMed Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Stephenson J, Tuncelli O, Gu T, et al. Adherence to oral second‐generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims. Int J Clin Pract 2012;66:565-73
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010;16:306-24
   PubMed Web of Science ®Google Scholar
• Přikryl R, Přikrylová Kučerová H, Vrzalová M, et al. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treat 2012;2012;2012:764769
   PubMedGoogle Scholar
• Pilon D, Tandon N, Lafeuille M-H, et al. Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther 2017;39:1972-85.e1972
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Special Pharm 2015;21:754-69
   PubMed Web of Science ®Google Scholar
• Benson CJ, Joshi K, Lapane KL, et al. Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics. Curr Med Res Opin 2015;31:1437-48
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 2018;21:127-34
   PubMed Web of Science ®Google Scholar
• Raedler LA. Aripiprazole lauroxil (Aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia. Am Health Drug Benef 2016;9(Spec Feature):40-3
   PubMedGoogle Scholar
• Velligan DI, Medellin E, Draper M, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Commun Ment Health J 2011;47:654-9
   PubMed Web of Science ®Google Scholar
• Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl. 2009;52:S1-4
   Google Scholar
• Getzen H, Beasley M, D’mello DA. Barriers to utilizing long-acting injectable antipsychotic medications. Ann Clin Psychiatry 2013;25:E1-E6
   PubMedGoogle Scholar
• Velligan DI, Mueller J, Wang M, et al. Use of environmental supports among patients with schizophrenia. Psychiatr Serv 2006;57:219-24
   PubMed Web of Science ®Google Scholar
• Hamann J, Heres S, Seemann U, et al. Effects of an integrated care program for outpatients with affective or psychotic disorders. Psychiatry Res 2014;217:15-19
   PubMed Web of Science ®Google Scholar
• ZYPREXA RELPREVV patient care program instructions brochure. 2016. Available at: https://www.zyprexarelprevvprogram.com/PDF/Lilly%20Zyprexa%20Relprevv%20Folder%20Booklet.pdf [Last accessed September 13, 2018]
   Google Scholar
• ARISTADA Care Program. 2018. Available at: https://www.aristadacaresupport.com/assistance-programs [Last accessed October 10, 2018]
   Google Scholar
• The ASSURE Program from Otsuka. 2018. Available at: https://www.assure.com/ [Last accessed September 10, 2018]
   Google Scholar
• Burudpakdee C, Khan ZM, Gala S, et al. Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis. Patient Prefer Adher 2015;9:435
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Wilk J, et al. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv 2006;57:205-11
   PubMed Web of Science ®Google Scholar